Vigil Neuroscience study for Alzheimer’s drug to proceed with FDA restrictions (VIGL)
Iryna Drozd Vigil Neuroscience (NASDAQ:VIGL) said the FDA is allowing a Phase 1 clinical trial for its Alzheimer’s drug candidate ...
Iryna Drozd Vigil Neuroscience (NASDAQ:VIGL) said the FDA is allowing a Phase 1 clinical trial for its Alzheimer’s drug candidate ...
Copyright © 2022 - Index Investing News.
Index Investing News is not responsible for the content of external sites.